Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
The detection of tumor-associated fibrosis in colorectal peritoneal metastases by FAPI-PET (TROMPET)
Disc Medicine
Metastatic colorectal cancer
1 trial -
The pivotal bioequivalence study comparing the test product to the reference product, which belong to the group of medicines used in treatment of uncomplicated lower urinary tract infections.
Sciencepharma Sp. z o.o
Not applicable (submitted trial is a bioequivalence in healthy subjects)
1 trial -
Therapeutic Workplace Intervention
BRIGHT MINDS BIOSCIENCES INC.
Drug Addiction
1 trial -
This is a clinical trial (study), to be conducted at multiple clinical sites, of an oral study drug (EP262) that will be investigated in adult participants with Chronic Inducible Urticaria (CIndU) to assess if it is safe and improves reactions to known CIndU triggers.
Lacuna Pharma Pty Ltd
Chronic Inducible Urticaria
1 trial -
ThisCART22 cells injection
The First People's Hospital of Lianyungang
B Cell Malignancy
1 trial -
Tissue Plasminogen Activator (tPA)
Hospital Authority, Hong Kong
Peritoneal Dialysis
1 trial -
Treatment of Respiratory Complications Associated with COVID-19, Influenza A, Metapneumovirus, Respiratory Syncytial Virus (RSV) Infection Using Wharton’s Jelly (WJ)-Umbilical Cord (UC) Mesenchymal Stromal Cells (ProTrans®): open Phase IB Clinical Trial
Lacuna Pharma Pty Ltd
Respiratory viral disease, COVID-19, Influenza A, Metapneumovirus, Respiratory syncytial virus Infection
1 trial -
Trial to assess the safety and antitumor activity of GEN1057 on malignant solid tumors
Genmab A/S
Metastatic or advanced malignant solid tumors
1 trial -
Triprorelin for injection
The First People's Hospital of Lianyungang
Prostate Cancer (CRPC)
1 trial -
UB-421 SC
United Therapeutics Europe Ltd
HIV-1-infection
1 trial -
UB-421 SC(dB4C7C22-6 mAb)
United Therapeutics Europe Ltd
HIV-1 Infection
1 trial -
UB-621
United Therapeutics Europe Ltd
Herpes Simplex Virus Infection
1 trial -
UTAA09 injection
The First People's Hospital of Lianyungang
Recurrent or Refractory B-cell Non Hodgkin's Lymphoma
1 trial -
UTAA91 injection
Suzhou Ribo Life Science Co.
Rheumatoid Arthritis (RA)
1 trial -
UTAA91 injection
Hospital Authority, Hong Kong
Rheumatoid Arthritis (RA)
1 trial -
VCH 916
Vertex Pharmaceuticals (Australia) Pty.
HCV Infection
1 trial -
VGX-3100
INOVIO PHARMACEUTICALS, INC.
Papillomavirus Infections
1 trial -
VIR-1111
Vir Biotechnology
HIV I Infection
1 trial -
VSA001 injection
Arrowhead Pharmaceuticals Ireland Limited
Healthy Adult Volunteers
1 trial -
Vadadustat
Akebia Europe Limited
Drug Interaction Potentiation
4 trials -
Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) 5 µg
Hospital Authority, Hong Kong
COVID-19 Pandemic
1 trial -
Valemetostat Tosylate, DS-8201a, Datopotamab deruxtecan, Valemetostat Tosylate, Valemetostat Tosylate
Daiichi Sankyo
This study will be a Phase 1b, global, multicenter, open-label, 2-part study of valemetostat in combination with DXd ADCs. The Master Protocol study design contains independent subprotocols, which have been defined by treatment combination and subject population, as follows: Sub-protocol A: Valemetostat in combination with T-DXd in subjects with previously treated, unresectable and/or metastatic HER2-low (immunohistochemistry[IHC] 1+ or IHC 2+/in situ hybridization [ISH]-negative) BC; for details, see Sub-protocol A. Sub-protocol B: Valemetostat in combination with T-DXd in subjects with previously treated, advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma; for details, see Sub-protocol B. Sub-protocol C: Valemetostat in combination with Dato-DXd in subjects with previously treated, locally advanced, unresectable, or metastatic non-squamous NSCLC with or without actionable genomic alteration(s); for details, see Sub-protocol C.
1 trial -
Varenicline
BRIGHT MINDS BIOSCIENCES INC.
Drug Addiction
1 trial -
Varenicline Tartrate
BRIGHT MINDS BIOSCIENCES INC.
Nicotine Addiction
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources